Abstract: Substantially pure C. albicans topoisomerase I protein is disclosed. Nucleic acid molecules that encode C. albicans topoisomerase I protein, recombinant expression vectors that comprise a nucleic acid sequence that encodes C. albicans topoisomerase I protein, and host cells that comprise recombinant expression vectors that comprise nucleic acid sequences that encode C. albicans topoisomerase I protein are disclosed. Fragments of nucleic acid molecules with sequences encoding C. albicans topoisomerase I protein and oligonucleotide molecules that comprise a nucleotide sequence complementary to fragment of a nucleotide sequence that encodes C. albicans topoisomerase I protein are disclosed. Antibodies which bind to an epitope on C. albicans topoisomerase I protein are disclosed. Methods of identifying inhibitors of C. albicans topoisomerase I protein are disclosed. Camptothecin analogs useful as inhibitors of C.

Abstract: The invention concerns the use of duplex oligonucleotides having both 2'-deoxyribonucleotides and ribonucleotides, wherein there is base pairing between the two types of nucleotides. The sequence of the oligonucleotide is selected so that the 3' and 5' most regions of the oligonucleotide are homologous with (identical to) the sequence of a preselected target gene of a cell. The two regions of homology embrace a region that is heterologous with the target sequence. The introduction of the oligonucleotide into the nucleus of the cell causes the alteration of the target gene such that the sequence of the altered target gene is the sequence of the heterologous region. Consequently, the oligonucleotides of the invention are termed Chimeric Repair Vectors (CRV). In one embodiment of the invention the target gene is a globin gene and the target cell is a hematopoietic stem cell. This embodiment can be used to correct certain hemoglobinopathies such as Sickle Cell Disease, .beta.

Abstract: Substantially pure C. albicans topoisomerase I protein is disclosed. Nucleic acid molecules that encode C. albicans topoisomerase I protein, recombinant expression vectors that comprise a nucleic acid sequence that encodes C. albicans topoisomerase I protein, and host cells that comprise recombinant expression vectors that comprise nucleic acid sequences that encode C. albicans topoisomerase I protein are disclosed. Fragments of nucleic acid molecules with sequences encoding C. albicans topoisomerase I protein and oligonucleotide molecules that comprise a nucleotide sequence complimentary to fragment of a nucleotide sequence that encodes C. albicans topoisomerase I protein are disclosed. Antibodies which bind to an epitope on C. albicans topoisomerase I protein are disclosed. Methods of identifying inhibitors of C. albicans topoisomerase I protein are disclosed.